Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what percentage of cancer therapies assessed by the National Institute of Health and Care Excellence (NICE) have been for combination therapies rather than monotherapies in each year since 2017; and what percentage of terminated NICE appraisals for cancer therapies have been for combination therapies rather than monotherapies in each year since 2017.

Between 1 January 2017 and 31 December 2022, 27% of cancer appraisal recommendations made by the National Institute for Health and Care Excellence related to combination therapies and 38% of terminated cancer drug appraisals related to combination therapies.